Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Recent randomized controlled trials in acute pancreatitis have provided evidence that challenges current approaches to management, including fluid resuscitation, antibiotic administration, management of infected necrosis and use of early endoscopic retrograde cholangiopancreatography. The evidence means that we need to reassess the current management guidelines.
Inflammatory bowel disease (IBD) clinical trials face a recruitment crisis. This is attributable to multiple individual trials competing for the same pool of participants, growing sample size demands and the increased availability of licensed alternative options for many potential participants. We need phase II trials that are more efficient both in design and in outcomes measured in order to deliver earlier and more precise answers, rather than simply offering a crude preview of what a subsequent phase III trial might look like.
In this Comment, we provide a strategic framework for what could and should be measured, across four domains, to optimize standards of care for multidisciplinary models of care in nonalcoholic fatty liver disease.
This Review discusses the role of the circadian clock in liver homeostasis, and how dysfunction of the liver circadian clock is associated with several liver-related diseases, including nonalcoholic fatty liver disease, type 2 diabetes mellitus and hepatocellular carcinoma.
Currently, systematic care for adults and adolescents with oesophageal atresia–tracheoesophageal fistula (EA-TEF) as they transition into adulthood is lacking. A multidisciplinary group of experts structured this Consensus Statement offering guidelines for the care of adolescents and adults with EA-TEF during transition.
Tackling fibrosis in patients with nonalcoholic steatohepatitis (NASH), one of the major causes of liver cirrhosis, is critical in improving patient outcomes. This Perspective discusses potential strategies to develop better antifibrotic therapies in NASH, from the discovery process to future clinical trials.
Up to one-third of people with irritable bowel syndrome (IBS) also experience anxiety or depression. In this Review, we highlight common challenges that arise when managing patients with IBS and co-occurring anxiety and depression, and provide recommendations for tailoring clinical assessment and treatment.
Single-cell profiling studies of the human gastrointestinal tract are increasing, offering an excellent opportunity to generate the first Human Gut Cell Atlas. This Roadmap presents a structured direction towards this goal and provides a detailed overview of the major challenges.
In gastroenterology, ChatGPT and large language models (LLMs) can assist clinicians in various tasks but also have several shortcomings. Although LLMs have great potential to assist clinicians in health care, they should be used as a tool to support, rather than replace, human expertise.